MEDS · XBRL financial data
DataMeds AI financial statements, every fiscal year
The same tables from 3 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (MEDS's year ends in late December)
| In thousands of dollars | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|
| Revenue from contracts with customers | 18,129 | 23,338 |
| Cost of revenue | 16,362 | 29,764 |
| Gross profit | 1,767 | (6,426) |
| General and administrative | 6,798 | 70,333 |
| Total operating expenses | 7,912 | 87,323 |
| Operating income (loss) | (6,145) | (93,749) |
| Interest expense | 831 | 4,580 |
| Net income (loss) | (6,856) | (101,275) |
| Earnings per share, basic USD per share | (0.15) | (1.43) |
| Earnings per share, diluted USD per share | (0.15) | (1.43) |
| Weighted average shares, basic thousands of shares | 47,252 | 70,986 |
| Weighted average shares, diluted thousands of shares | 47,252 | 70,986 |
- † Share count changed about 2x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (MEDS's year ends in late December)
| In thousands of dollars | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|
| Cash and cash equivalents | 1,028 | 43 |
| Accounts receivable | — | 1,137 |
| Inventory | 9,519 | 1,639 |
| Total current assets | 15,169 | 2,819 |
| Property and equipment, net | 388 | 229 |
| Right-of-use asset | 1,528 | 967 |
| Goodwill | 16,220 | 14,194 |
| Total assets | 57,333 | 30,459 |
| Current portion of long-term debt | 11,455 | — |
| Total current liabilities | 38,047 | 29,780 |
| Long-term debt | 11,455 | 12,600 |
| Lease liability, non-current | 1,096 | 527 |
| Total liabilities | 50,598 | 42,907 |
| Accumulated deficit | (9,757) | (111,032) |
| Total stockholders' equity | 6,734 | (12,448) |
| Total liabilities and equity | 57,333 | 30,459 |
| Common shares outstanding (cover page) thousands of shares | 51,944 | 104,872 |
- † Share count changed about 2x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (MEDS's year ends in late December)
| In thousands of dollars | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|
| Net income (loss) | (6,856) | (101,275) |
| Stock-based compensation | 1,081 | 54,795 |
| Net cash from operating activities | (1,225) | (10,855) |
| Net cash from investing activities | 469 | (882) |
| Proceeds from issuing common stock | 10 | — |
| Net cash from financing activities | 1,783 | 10,751 |
| Net change in cash | 1,027 | (986) |
- † Share count changed about 2x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 5122 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 5122 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| DataMeds AI | 2,456 | 1,780 | (2,894)* | 3.1M | 0.8 quarters | 10-QJun 30, 2026 |
| Sharing Services Global | 730 | 2,085 | (421)* | 309,652 | 1.7 quarters | 10-QSep 30, 2024 |
| Cosmos Health | 1,801 | 18,986 | (1,718)* | 100.6M | 1.1 quarters | 10-QJun 30, 2026 |
| Stemtech | 247 | 629 | (55)* | 3.0B | 4.5 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.